PIP Search Page

Displaying 661 - 680 of 907

PIPS Search Results
PIP Number	Active Substance	Conditions / Indications	Invented Name	Therapeutic area	Decision Type	Compliance Check	Compliance outcome	Date Published Sort ascending
MHRA-100737-PIP01-22	Clazakizumab	Prevention and treatment of rejection of transplanted kidney		Immunology -Rheumatology-Transplantation	P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)	No		30/06/2023
MHRA-100371-PIP01-21	Ex vivo expanded autologous human keratinocytes containing epidermal stem cells genetically modified with a gamma-retroviral (RV) vector expressing the full-length LAMB3 cDNA	Treatment of Junctional Epidermolysis Bullosa (JEB)	HOLOGENE 5	Dermatology	P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)	No		30/06/2023
MHRA-100792-PIP01-22	OBINUTUZUMAB	Prevention of cytokine release syndrome induced by anti CD20/CD3 antibodies	Gazyvaro	Oncology	P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)	No		30/06/2023
MHRA-100466-PIP01-22	zilovertamab vedotin	Treatment of malignant neoplasms of haematopoietic and lymphoid tissue Treatment of all conditions included in the category of malignant neoplasms (except nervous system, haematopoietic, and lymphoid tissue)	not available at present	Oncology	P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)	No		30/06/2023
MHRA-100706-PIP01-22	METHYLPHENIDATE HYDROCHLORIDE	Treatment of attention-deficit hyperactivity disorder	Not available at present Methylphenidate hydrochloride Methylphenidate hydrochloride Methylphenidate hydrochloride Methylphenidate hydrochloride	Neurology	P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)	Yes		30/06/2023
MHRA-100845-PIP01-23-M02 (update)	CABOTEGRAVIR	Prevention of human immunodeficiency virus (HIV-1) infection	N/A VOCABRIA AND APRETUDE Apretude N/A N/A N/A Apretude Apretude	Infectious diseases	PM: decision on the application for modification of an agreed paediatric investigation plan.	Yes	Full Compliance Check Granted	20/06/2023
MHRA-100126-PIP01-21-M01 (update)	Adeno-associated viral vector serotype 9 containing the human mini-dystrophin gene	Duchenne Muscular Dystrophy	fordadistrogene movaparvovec	Neurology	P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)	No		15/06/2023
MHRA-100598-PIP01-22	Cobolimab	Treatment of lung cancer	Not available at present	Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No		25/05/2023
MHRA-100587-PIP01-22	lusvertikimab	Treatment of Sjögren’s syndrome		Immunology -Rheumatology-Transplantation	W: decision granting a waiver in all age groups for the listed condition(s).	No		25/05/2023
MHRA-100577-PIP01-22	ziltivekimab	Treatment of heart failure	Not available at present	Cardiovascular Diseases	W: decision granting a waiver in all age groups for the listed condition(s).	No		25/05/2023
MHRA-100603-PIP01-22	Oleclumab	Treatment of lung cancer Treatment of pancreatic cancer		Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No		25/05/2023
MHRA-100602-PIP01-22	monalizumab	Treatment of lung cancer		Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No		25/05/2023
MHRA-100583-PIP01-22	SACITUZUMAB GOVITECAN	Treatment of lung carcinoma (small-cell and non-small-cell carcinoma)	Trodelvy Trodelvy Trodelvy	Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No		25/05/2023
MHRA-100599-PIP01-22	Flortaucipir F18	Diagnosis of Alzheimer's disease	Tauvid Tauvid	Neurology	W: decision granting a waiver in all age groups for the listed condition(s).	No		25/05/2023
MHRA-100555-PIP01-22	vepsitamab	Treatment of gastric cancer and gastro-oesophageal junction cancer Treatment of colorectal carcinoma Treatment of pancreatic cancer		Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No		25/05/2023
MHRA-100565-PIP01-22	MDM2-p53 antagonist	Treatment of liposarcoma		Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No		25/05/2023
MHRA-100493-PIP01-22	BI 765128 - humanized monoclonal antibody of IgG1 subtype targeting NRP1	Diabetic retinopathy		Ophthamology	W: decision granting a waiver in all age groups for the listed condition(s).	No		25/05/2023
MHRA-100884-PIP01-23-M01 (update)	SACUBITRIL VALSARTAN	Treatment of Heart failure	Entresto Entresto Entresto Entresto Entresto Entresto Entresto Entresto Entresto Entresto Entresto Entresto Entresto Entresto Entresto Entresto Entresto Entresto Entresto Entresto Entresto Entresto Entresto Entresto Entresto Entresto Entresto Neparvis Neparvis Neparvis Neparvis Neparvis Neparvis Neparvis Neparvis Neparvis Neparvis Neparvis Neparvis Neparvis Neparvis Neparvis Neparvis Neparvis	Cardiovascular Diseases	PM: decision on the application for modification of an agreed paediatric investigation plan.	Yes	Full Compliance Check Granted	25/05/2023
MHRA-100817-PIP01-22-M01 (update)	SIPONIMOD	Treatment of Multiple Sclerosis		Neurology	PM: decision on the application for modification of an agreed paediatric investigation plan.	No		25/05/2023
MHRA-100815-PIP01-22-M01 (update)	SIPONIMOD	Treatment of Multiple Sclerosis	Mayzent Mayzent Mayzent Mayzent Mayzent Mayzent Mayzent Mayzent Mayzent Mayzent Mayzent Mayzent Mayzent Mayzent Kiendra Mayzent Mayzent Mayzent Kiendra Mayzent Kiendra Mayzent Mayzent Mayzent Mayzent Mayzent Mayzent Kiendra Mayzent Mayzent Mayzent Mayzent Mayzent Mayzent	Neurology	PM: decision on the application for modification of an agreed paediatric investigation plan.	No		25/05/2023

Download XLSX